The DOI matches its Crossref record; 64 of the 65 references it cites were found in a registry or an index.
Hypoxia-Inducible Factors Regulate Tumorigenic Capacity of Glioma Stem Cells
Open accessAbstract
Glioblastomas are lethal cancers characterized by florid angiogenesis promoted in part by glioma stem cells (GSCs). Because hypoxia regulates angiogenesis, we examined hypoxic responses in GSCs. We now demonstrate that hypoxia-inducible factor HIF2alpha and multiple HIF-regulated genes are preferentially expressed in GSCs in comparison to non-stem tumor cells and normal neural progenitors. In tumor specimens, HIF2alpha colocalizes with cancer stem cell markers. Targeting HIFs in GSCs inhibits self-renewal, proliferation, and survival in vitro, and attenuates tumor initiation potential of GSCs in vivo. Analysis of a molecular database reveals that HIF2A expression correlates with poor glioma patient survival. Our results demonstrate that GSCs differentially respond to hypoxia with distinct HIF induction patterns, and HIF2alpha might represent a promising target for antiglioblastoma therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Since HIF-2α is strongly expressed in the cytoplasm of NB tumor cells at physiological oxygen levels (5% O2), this could suggest additional largely unexplored functions of HIF-2α in the cytoplasm, independent of HIF-1β-dependent transcription, such as regulation of mRNA translation [9,43].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [43]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In NB clinical specimens, HIF-1α expression negatively correlates with the presence of blood vessels indicating that HIF-1α is expressed exclusively in hypoxic cells [43].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [43]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, HIF-2α is located in dense clusters of cells adjacent to blood vessels, referred to as the perivascular niche, which have a neural crest-like phenotype, and are HIF-1α negative, suggesting they are not hypoxic [43].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [43]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, treatment with PT2385 had no effect on tumor growth, did not impact transcription of HIF target genes and did not modulate chemotherapy response [43].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [43]
Experimental — accuracy not yet measuredIn the citing paper
“Given that HIF-2α is an important transcription factor in cancer progression and leads to poor prognosis69,70”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [70]
In the citing paper
“Hypoxia was first shown to induce the CSC phenotype in glioma [77] and, subsequently, in breast cancer [78, 79], in a HIF-dependent manner.”
From The hypoxic tumor microenvironment: A driving force for breast cancer progression (2016) · cites this paper as [77]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Identification of human brain tumour initiating cells
Singh, S. K., Hawkins, C. E., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,564
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,517
Self-citationHypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma
Galli, R., Binda, E., Orfanelli, U., Cipelletti, B., Gritti, A., Vitis, S. D., Fiocco, R., Foroni, C., DiMeco, F., & Vescovi, A. L. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1364 · Cited by 2,570
Plate, K. H., Breier, G., Weich, H. A., & Risau, W. (1992) · Nature · doi:10.1038/359845a0 · Cited by 2,262
A Perivascular Niche for Brain Tumor Stem Cells
Calabrese, C. R., Poppleton, H., Koçak, M., Hogg, T. L., Fuller, C. E., Hamner, J. B., Oh, E. Y., Gaber, M. W., Finklestein, D., Allen, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.020 · Cited by 2,253
Hypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma
Liu, G., Yuan, X., Zeng, Z., Tunici, P., Ng, H., Abdulkadir, I. R., Lu, L., Irvin, D. K., Black, K. L., & Yu, J. S. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-67 · Cited by 1,844
Cancerous stem cells can arise from pediatric brain tumors
Hemmati, H. D., Nakano, I., Lazareff, J. A., Masterman-Smith, M. D., Geschwind, D. H., Bronner-Fraser, M. E., & Kornblum, H. I. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2036535100 · Cited by 1,842
Cited by
Sorted by citations
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063
Hypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380
Targeting cancer stem cell pathways for cancer therapy
Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., Zhang, G., Wang, X., Dong, Z., Chen, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0110-5 · Cited by 1,957
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01332-8 · Cited by 1,612
Metadata
- Authors
- Li, Z., Bao, S., Wu, Q., Wang, H., Eyler, C., Sathornsumetee, S., Shi, Q., Cao, Y., Lathia, J., McLendon, R. E., Hjelmeland, A. B., & Rich, J. N.
- Affiliations
- Duke Medical Center (US)
- Cleveland Clinic (US)
- Corresponding author
- Rich, Jeremy N.
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2009-06
- Volume
- 15
- Issue
- 6
- Pages
- 501-513
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC2693960
- OpenAlex
- W2039075677
- Cited by
- 1,354
- References
- 65
- Citations by year
- 2026: 41 · 2025: 40 · 2024: 49 · 2023: 72 · 2022: 92 · 2021: 98 · 2020: 72 · 2019: 75 · 2018: 74 · 2017: 93 · 2016: 97 · 2015: 97 · 2014: 96 · 2013: 80 · 2012: 101
- FWCI
- 30.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA 116659, R01CA116659, CA112958, R01CA129958)
- National Institute of Neurological Disorders and Stroke (K02NS047409, R01NS054276, NS054276, NS047409)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- HIF-2α, glioma stem cells, glioblastoma, hypoxia, angiogenesis, self-renewal, tumor initiation, cancer stem cell markers, patient survival, therapeutic target
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Animals, Brain Neoplasms, Cell Survival, Cells, Cultured, Glioblastoma, Humans, Mice, Inbred BALB C, Mice, Nude, Neoplasm Transplantation, Neovascularization, Pathologic, Stem Cells, Biomarkers, Tumor, Neoplastic Stem Cells, Cell Hypoxia, Vascular Endothelial Growth Factor A, Cell Proliferation, Mice, Basic Helix-Loop-Helix Proteins, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
